Evidence map›Paper›PMID 42882491›Full record

ReviewCells2026

From Amyloid Exposure to Genetic Causality: Converging hiPSC-Based Models of Alzheimer's Disease.

Fiorella Colasuonno, Alessio Valenza, Federica Rossin, Sandra Moreno

Abstract readReview
In one paragraph

Review in Cells, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Fiorella ColasuonnoDepartment of Experimental Medicine, University of Rome "Tor Vergata", 00133 Rome, Italy.ORCID 0000-0002-4894-5084
Alessio ValenzaDepartment of Science, University Roma Tre, 00146 Rome, Italy.ORCID 0009-0009-4178-671X
Federica RossinDepartment of Biology, University of Rome "Tor Vergata", 00133 Rome, Italy.
Sandra MorenoDepartment of Science, University Roma Tre, 00146 Rome, Italy.ORCID 0000-0002-1079-3222

Funding

Italian Alzheimer Research Association Onlus AGYR2020Italian Association for Cancer Research 27116Ministero della Salute PNRR-MAD-2022-12375639Ministero dell'università e della ricerca Grant of Excellence Department 2023-2027Ministry of Universities and Research PNRR (DM 629) CUP: F81J24000490006Ministry of Universities and Research PNRR-MAC2-II.3 project PE6 "Heal Italia" CUP E83C22004670001Ministry of Universities and Research PRIN 2022, CUP E53D23007150006
6 · The paper itself

Abstract

Alzheimer's disease (AD) is a neurodegenerative disorder in which genetic susceptibility, aging, protein aggregation, and neuroglial dysfunction converge to drive progressive neuronal loss. Although animal models and conventional cell systems have provided fundamental insights into pathomechanisms, they only partially reproduce the human-specific and multifactorial nature of AD. Human induced pluripotent stem cell (hiPSC)-based models have emerged as a powerful platform to investigate disease-relevant processes within a patient-specific genetic background while enabling the generation of multiple neural cell types and multicellular systems. In this review, we present the evolution of hiPSC-based AD modeling, from reductionist paradigms based on exogenous amyloid-β exposure to CRISPR-engineered isogenic models addressing causal mutations and genetic risk variants associated with either familial or sporadic forms. We examine the contribution of three-dimensional brain organoids and neuroglial co-culture systems in recapitulating cell-cell interactions, neuroinflammatory responses, and tissue-level pathological processes. We focus on current challenges, including the limited representation of neuronal aging, variability among organoids, and the need for standardized protocols. Finally, we discuss the translational potential of hiPSC-derived systems for target identification, drug discovery, and regenerative medicine. Collectively, these advances position hiPSC-based platforms as essential complementary models for elucidating AD pathogenesis and accelerating the development of precision therapeutic strategies.

Indexed as

Alzheimer DiseaseAmyloidAmyloid beta-PeptidesInduced Pluripotent Stem CellsModels, BiologicalAnimalsHumansNeurogliaOrganoidsAmyloidAmyloid beta-PeptidesAlzheimer’s diseaseCRISPRiPSneuroglianeuroinflammationorganoidsregenerative medicinestem cell therapyβ-amyloid

Identifiers

PMID42882491
PMCPMC13664262

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.